<DOC>
	<DOCNO>NCT01628445</DOCNO>
	<brief_summary>Liraglutide GLP1 agonist use treatment Type 2 diabetes asociated improved blood glucose control , weight loss low rate hypoglycemia use alone combination metformin . Liraglutide extensively test people type 2 diabetes take relatively large dos insulin ( &gt; 50 U/day ) . Often patient insulin resistant despite use large dos insulin able achieve glucose target . The rationale study assess addition liraglutide addition usual care versus placebo improve blood glucose level people achieve target HbA1C le 7.0 % .</brief_summary>
	<brief_title>Study Liraglutide Individuals With Type 2 Diabetes Using Insulin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes BMI≤45 kg/m2 A1c ≥7.5 % ≤10.5 % type 1 diabetes symptom poorly control diabetes eGFR &lt; 50 ml/min/1.73m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Insulin</keyword>
</DOC>